A Mutated Prostatic Acid Phosphatase (PAP) Peptide-Based Vaccine Induces PAP-Specific CD8+ T Cells with Ex Vivo Cytotoxic Capacities in HHDII/DR1 Transgenic Mice

A Mutated Prostatic Acid Phosphatase (PAP) Peptide-Based Vaccine Induces PAP-Specific CD8+ T Cells with Ex Vivo Cytotoxic Capacities in HHDII/DR1 Transgenic Mice

Background: Current treatments for castrate (hormone)-resistant prostate cancer (CRPC) remain limited and are not curative, with a median survival from diagnosis of 23 months. The PAP-specific Sipuleucel-T vaccine, which was approved by the FDA in 2010, increases the Overall Survival (OS) by 4 month...

Full description

Bibliographic Details
Main Authors: Cavaignac, M. (Author), Christensen, D. (Author), Idri, S. (Author), Khan, M.A (Author), McArdle, S.E (Author), Nicholls, H. (Author), Pockley, A.G (Author), Reeder, S. (Author), Vadakekolathu, J. (Author), Vu, P.L (Author)
Format: Article
Language:English
Published: MDPI 2022
Subjects:
CAF®09
castrate (hormone)-resistant PCa (CRPC)
Dextramer™
HHDII/DR1 mice
immunotherapy
PBMC
prostate cancer
prostatic acid phosphatase (PAP)
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items